Online Only Articles

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano
Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano
Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara
Hematology Division, University of Torino and Center for Experimental Research and Medical Studies, Torino
Oncology and Hematology Unit, General Hospital, Nocera Inferiore, Pavia
Department of Oncology-Hematology, Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia
Hematology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Milan
Lymphoma Unit, Department of Onco-Hematology, San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan
Division of Hematology, Spedali Civili, Brescia
Hematology Division, Cuneo Hospital, Milano, Italy
Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano
Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara
Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara
Service of Biostatistics, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano, Italy
Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano
Hematology Division, University of Torino and Center for Experimental Research and Medical Studies, Torino
Vol. 99 No. 9 (2014): September, 2014 https://doi.org/10.3324/haematol.2014.106740